Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 203 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: quetiapine Clear all
Completed Not applicable Interventional

Quetiapine vs Haloperidol Decanoate for the Long Term Treatment of Schizophrenia and Schizoaffective Disorder

NCT00018642
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine, haloperidol decanoate
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 21, 2009 · Synced Oct 17, 2026, 4:53 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Clinical Utility of Antipsychotic Medication Levels in Plasma as Determined by Liquid Chromatography-Tandem Mass Spectrometry

NCT02462473
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Aripiprazole, Olanzapine, Paliperidone, Quetiapine, Risperidone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Torrance, California • Kissimmee, Florida • Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression

NCT00060489
View directory record Official record
Conditions
Bipolar Disorder, Depression, Bipolar
Interventions
SEROQUEL (quetiapine fumarate) Tablets
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
27
States / cities
Birmingham, Alabama • Beverly Hills, California • La Mesa, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2011 · Synced Oct 17, 2026, 4:53 AM EDT
Terminated Phase 3 Interventional

Depakote Extended Release (ER) Versus Seroquel for Agitated Behaviors in Nursing Home Care Unit Patients With Dementia

NCT00315900
View directory record Official record
Conditions
Agitation, Dementia
Interventions
Depakote ER, Seroquel
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
55 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 27, 2017 · Synced Oct 17, 2026, 4:53 AM EDT
Terminated Phase 4 Interventional Results available

Anxiety in Recovering Opiate Dependence

NCT00668265
View directory record Official record
Conditions
Generalized Anxiety Disorder, Comorbid Opiate Dependence in Remission, Status Post Methadone-Maintenance Treatment
Interventions
Quetiapine
Drug
Lead sponsor
Beth Israel Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 18, 2013 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 4 Interventional

Quetiapine Compared With Placebo in the Management of Fibromyalgia

NCT01458964
View directory record Official record
Conditions
Fibromyalgia
Interventions
Quetiapine
Drug
Lead sponsor
East Tennessee State University
Other
Eligibility
18 Years to 60 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Johnson City, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 9, 2014 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 4 Interventional Results available

Acute Psychotherapy for Bipolar II Depression

NCT01133821
View directory record Official record
Conditions
Bipolar Disorder, Depression
Interventions
IPSRT plus placebo (IPSRT-PLA), IPSRT plus quetiapine
Drug
Lead sponsor
Holly Swartz
Other
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia.

NCT04115319
View directory record Official record
Conditions
Schizophrenia
Interventions
SEP363856, quetiapine XR
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
18
States / cities
Cerritos, California • Oakland, California • Oceanside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 3 Interventional

Quetiapine Fumarate (Seroquel) for the Treatment of Alcohol Dependence.

NCT00124059
View directory record Official record
Conditions
Alcoholism
Interventions
Seroquel, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2015 · Synced Oct 17, 2026, 4:53 AM EDT
Completed No phase listed Observational

Pharmacokinetics of Quetiapine Across Pregnancy and Postpartum

NCT02978534
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Quetiapine
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2022 · Synced Oct 17, 2026, 4:53 AM EDT
Active, not recruiting Phase 4 Interventional

Sequential Multiple Assignment Randomized Trial for Bipolar Depression

NCT06433635
View directory record Official record
Conditions
Bipolar I Disorder, Depression
Interventions
Cariprazine, Aripiprazole/Escitalopram combination, Quetiapine, Lurasidone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
2,726 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
17
States / cities
Birmingham, Alabama • Bloomington, Indiana • Baltimore, Maryland + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 17, 2026, 4:53 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis

NCT04373317
View directory record Official record
Conditions
Parkinson's Disease Psychosis
Interventions
Pimavanserin, Quetiapine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years and older
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
24
States / cities
Tucson, Arizona • Loma Linda, California • Palo Alto, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 4 Interventional

Treatment and Outcome of Early Onset Bipolar Disorder

NCT00048802
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium, Olanzapine, Divalproex, Risperidone, Quetiapine, Ziprasidone, Aripriprazole
Drug
Lead sponsor
Northwell Health
Other
Eligibility
10 Years to 18 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Glen Oaks, New York
Source: ClinicalTrials.gov public record
Updated Jan 22, 2014 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study Comparing Topical, Rectal, and Oral Quetiapine

NCT02131545
View directory record Official record
Conditions
Dementia, Delirium
Interventions
Quetiapine 25 mg gel applied topically, Quetiapine 25 mg tablet by mouth, Quetiapine 25 mg rectal suppository
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 25, 2017 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 4 Interventional Results available

A Study of the Cataractogenic Potential of Seroquel and Risperdal in the Treatment of Participants With Schizophrenia or Schizoaffective Disorder

NCT00206102
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
quetiapine fumarate, risperidone
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
1,098 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
63
States / cities
Little Rock, Arkansas • Mabelvale, Arkansas • Morrilton, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2013 · Synced Oct 17, 2026, 4:53 AM EDT
Completed No phase listed Observational

Pioglitazone and Quetiapine XR Pharmacogenetic Study

NCT01342380
View directory record Official record
Conditions
Bipolar Disorder, Major Depressive Disorder
Interventions
Not listed
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 18, 2023 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Cardiovascular Biomarkers and Quetiapine in Depression and Anxiety Patients

NCT00951483
View directory record Official record
Conditions
Depression, Anxiety
Interventions
Quetiapine-XR
Drug
Lead sponsor
Loyola University
Other
Eligibility
20 Years to 65 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 24, 2016 · Synced Oct 17, 2026, 4:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Schizophrenia Sensory Gating Deficit With Quetiapine

NCT00536783
View directory record Official record
Conditions
Schizophrenia
Interventions
Quetiapine
Drug
Lead sponsor
New Mexico VA Healthcare System
Federal
Eligibility
18 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 31, 2007 · Synced Oct 17, 2026, 4:53 AM EDT
Completed No phase listed Observational

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

NCT02600741
View directory record Official record
Conditions
Schizophrenia
Interventions
Caregiver psycho-education and skills training, Caregiver support available at the study site, Paliperidone palmitate, Chlorpromazine, Droperidol, Fluphenazine, Haloperidol, Loxapine, Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Thioridazine, Trifluoperazine, Aripiprazole, Asenapine, Clozapine, Iloperidone, Olanzapine, Paliperidone, Quetiapine, Risperidone, Ziprasidone
Other · Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
34
States / cities
Bullhead City, Arizona • Oceanside, California • Denver, Colorado + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 17, 2026, 4:53 AM EDT
Terminated No phase listed Observational

Trazodone vs. Quetiapine for the Treatment of ICU Delirium

NCT05307003
View directory record Official record
Conditions
Delirium, Delirium of Mixed Origin, Delirium, Sepsis Associated, Delirium in Old Age, Delirium Confusional State, Psych, Morality, Treatment Side Effects
Interventions
Trazodone, Quetiapine
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

Movement Disorders Caused by Antipsychotic Drugs in Older Patients

NCT00255879
View directory record Official record
Conditions
Dyskinesia, Drug-Induced
Interventions
Quetiapine, Risperidone, Olanzapine
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
40 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 6, 2013 · Synced Oct 17, 2026, 4:53 AM EDT
Completed No phase listed Observational

Functional and Neurochemical Brain Changes Bipolar Depression

NCT00608296
View directory record Official record
Conditions
Depression, Bipolar
Interventions
Not listed
Lead sponsor
University of Cincinnati
Other
Eligibility
12 Years to 35 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced Oct 17, 2026, 4:53 AM EDT
Terminated Phase 2 Interventional Results available

Baclofen Effects on Smoking Urge and Withdrawal

NCT00257894
View directory record Official record
Conditions
Nicotine Use Disorder, Nicotine Dependence, Smoking, Tobacco Use Disorder
Interventions
Baclofen, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Oct 17, 2026, 4:53 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Quetiapine SR and Divalproex Sodium ER in the Treatment of Anxiety in Bipolar Disorder With Panic Disorder and/or GAD

NCT00579280
View directory record Official record
Conditions
Bipolar Disorder, Panic Disorder, Generalized Anxiety Disorder
Interventions
quetiapine SR, divalproex sodium ER, placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 65 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
3
States / cities
Palo Alto, California • Tampa, Florida • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 11, 2020 · Synced Oct 17, 2026, 4:53 AM EDT